Management of neuropsychiatric adverse events in a prostate cancer patient undergoing chimeric antigen receptor T-cell immunotherapy (a phase I clinical trial): A case report

Ruijin Tang; Qiong Wang; Jing Han; Ming Shi

doi:10.1016/j.apjon.2023.100211

Management of neuropsychiatric adverse events in a prostate cancer patient undergoing chimeric antigen receptor T-cell immunotherapy (a phase I clinical trial): A case report

Asia Pac J Oncol Nurs. 2023 Mar 3;10(4):100211. doi: 10.1016/j.apjon.2023.100211. eCollection 2023 Apr.

Authors

Ruijin Tang¹, Qiong Wang², Jing Han¹, Ming Shi³

Affiliations

¹ School of Nursing, Xuzhou Medical University, Xuzhou, China.
² Department of Urology, Xuzhou Medical University Affiliated Hospital, Xuzhou, China.
³ National and Local Joint Engineering Laboratory of Tumor Biotherapy, The First Clinical College of Xuzhou Medical University, Xuzhou, China.

Abstract

In previous clinical trials, chimeric antigen receptor T-cell immunotherapy has shown preliminary efficacy in patients with malignant solid tumors. However, the occurrence of adverse events, particularly neuropsychiatric adverse events (eg, anxiety) and cognitive dysfunction, during the course of treatment may reduce patient compliance and pose a threat to their safety. Nurses are in a unique position to promptly identify and manage such complications, thereby facilitating early diagnosis and treatment, as well as improving clinical and patient outcomes. Moreover, nurses can promote compliance through the provision of psychological support to patients.

Keywords: Anxiety; CAR T-cell immunotherapy; Cancer care; Psychological support; Side effects.

Publication types

Case Reports